These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

28 related articles for article (PubMed ID: 15963636)

  • 1. A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium.
    Xu N; Zhang XC; Xiong JP; Fang WJ; Yu LF; Qian J; Zhang L
    BMC Cancer; 2007 Jun; 7():98. PubMed ID: 17559681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium.
    Dumez H; Gallardo E; Culine S; Galceran JC; Schöffski P; Droz JP; Extremera S; Szyldergemajn S; Fléchon A
    Mar Drugs; 2009 Sep; 7(3):451-63. PubMed ID: 19841725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.
    Allstadt SD; Rodriguez CO; Boostrom B; Rebhun RB; Skorupski KA
    J Vet Intern Med; 2015 Jan; 29(1):261-7. PubMed ID: 25619518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01).
    Culine S; Fléchon A; Guillot A; Le Moulec S; Pouessel D; Rolland F; Ravaud A; Houédé N; Mignot L; Joly F; Oudard S; Gourgou S
    Eur Urol; 2011 Dec; 60(6):1251-7. PubMed ID: 21924547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder.
    Bhattacharyya M; Powles T; Mutsvangwa K; Wilson P; Oliver T; Shamash J
    Urol Oncol; 2013 Aug; 31(6):878-82. PubMed ID: 21890383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy for bladder cancer in patients with impaired renal function.
    Nicholson S
    Nat Rev Urol; 2011 Nov; 9(1):52-7. PubMed ID: 22105318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond.
    Cheng T
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):153-60. PubMed ID: 18685414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function.
    Demery ME; Thézenas S; Pouessel D; Culine S
    Anticancer Drugs; 2012 Feb; 23(2):143-8. PubMed ID: 21934599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
    Vaishampayan UN; Faulkner JR; Small EJ; Redman BG; Keiser WL; Petrylak DP; Crawford ED
    Cancer; 2005 Oct; 104(8):1627-32. PubMed ID: 16138364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
    Kouno T; Ando M; Yonemori K; Matsumoto K; Shimizu C; Katsumata N; Komiyama M; Okajima E; Matsuoka N; Fujimoto H; Fujiwara Y
    Eur Urol; 2007 Oct; 52(4):1115-22. PubMed ID: 17433855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
    Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Sep; 14(9):828-32. PubMed ID: 17760750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer.
    Johannsen M; Sachs M; Roigas J; Hinke A; Staack A; Loening SA; Schnorr D; Wille AH
    Eur Urol; 2005 Aug; 48(2):246-51. PubMed ID: 15963636
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.